Bristol Myers Squibb Stock Rating Reaffirmed by TheStreet (BMY)
Bristol Myers Squibb (NYSE: BMY)‘s stock had its “buy” rating restated by analysts at TheStreet in a research report issued to clients and investors on Monday.
The analysts wrote, “Bristol-Myers Squibb Company (BMY) has been reiterated by TheStreet Ratings as a buy with a ratings score of A- . The company’s strengths can be seen in multiple areas, such as its expanding profit margins, solid stock price performance, growth in earnings per share, largely solid financial position with reasonable debt levels by most measures and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow.”
A number of other firms have also recently commented on BMY. Analysts at Bank of America downgraded shares of Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research note to investors on Monday. Separately, analysts at Cowen reiterated an “outperform” rating on shares of Bristol Myers Squibb in a research note to investors on Tuesday, February 19th. Finally, analysts at Jefferies Group raised their price target on shares of Bristol Myers Squibb from $39.00 to $41.00 in a research note to investors on Tuesday, February 12th. They now have a “buy” rating on the stock.
Six research analysts have rated the stock with a buy rating, one has given an overweight rating, thirteen have given a hold rating, and one has assigned a sell rating to the company’s stock. The company presently has a consensus rating of “overweight” and an average price target of $35.39.
Shares of Bristol Myers Squibb opened at 36.54 on Monday. Bristol Myers Squibb has a 52 week low of $30.64 and a 52 week high of $37.25. The stock’s 50-day moving average is currently $36.10. The company has a market cap of $59.829 billion and a P/E ratio of 32.03.
Bristol Myers Squibb last released its earnings data on Thursday, January 24th. The company reported $0.47 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.42 by $0.05. The company had revenue of $4.19 billion for the quarter, compared to the consensus estimate of $4.14 billion. During the same quarter last year, the company posted $0.53 earnings per share. Bristol Myers Squibb’s revenue was down 23.2% compared to the same quarter last year. Bristol Myers Squibb has set its FY13 guidance at $1.78-1.88 EPS. On average, analysts predict that Bristol Myers Squibb will post $1.84 earnings per share for the current fiscal year.
Bristol-Myers Squibb Company (BMS) is a global biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.
To view TheStreet’s full report, visit www.thestreetratings.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.